Suppr超能文献

肌内注射腺相关病毒血清型 8 载体基因转移可在载脂蛋白 A-I 基因缺失小鼠中安全且持续过表达功能性载脂蛋白 A-I/高密度脂蛋白。

Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer.

机构信息

Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

J Cardiovasc Pharmacol. 2009 Nov;54(5):405-11. doi: 10.1097/FJC.0b013e3181bad264.

Abstract

High levels of high-density lipoprotein (HDL) have protective effects against atherosclerosis and cardiovascular diseases. The postulated mechanism of action for these benefits is an enhanced reverse cholesterol transport. Apolipoprotein A-I (ApoA-I) is the major protein of HDL. The clinical benefits of raising ApoA-I/HDL have been clearly established by clinical and epidemiological studies. Despite these observations, there are not very effective pharmacological means for raising HDL. ApoA-I gene delivery by viral vectors seems a promising strategy to raise ApoA-I/HDL levels. Sustained gene expression in animals and humans has been attained using adeno-associated viral (AAV) vectors. The aim of the present study was to determine the efficiency, safety, and biological activity of human ApoA-I intramuscularly delivered using an AAV vector in mice. AAV serotype 8 vectors encoding for human ApoA-I transgene were administered intraportally and intramuscularly in ApoA-I- deficient animals. ApoA-I levels were measured every 2 weeks post administration. The effectiveness of the generated HDL was tested in vitro in cholesterol-loaded macrophages. The administration of the vectors resulted in a significant and sustained increase in ApoA-I and HDL plasma levels for up to 16 weeks at similar extent by both routes of administration. Activity of the generated HDL in removal of cholesterol from cholesterol-loaded macrophages was similar in both groups. Our data suggest that intramuscular AAV8-mediated gene transfer of human ApoA-I results in a significant and maintained increase in ApoA-I and functional HDL.

摘要

高密度脂蛋白(HDL)水平升高对动脉粥样硬化和心血管疾病具有保护作用。这种益处的作用机制推测是增强了反向胆固醇转运。载脂蛋白 A-I(ApoA-I)是 HDL 的主要蛋白。临床和流行病学研究清楚地证实了提高 ApoA-I/HDL 的临床益处。尽管有这些观察结果,但目前并没有非常有效的药物手段来提高 HDL。病毒载体介导的 ApoA-I 基因传递似乎是提高 ApoA-I/HDL 水平的有前途的策略。腺相关病毒(AAV)载体在动物和人类中已实现了持续的基因表达。本研究的目的是确定 AAV 载体肌内递送人 ApoA-I 在小鼠中的效率、安全性和生物学活性。用编码人 ApoA-I 转基因的 AAV 血清型 8 载体经门静脉内和肌内给药于 ApoA-I 缺乏的动物。给药后每 2 周测量一次 ApoA-I 水平。在体外,用载脂蛋白负载的巨噬细胞测试生成的 HDL 的有效性。两种给药途径均导致 ApoA-I 和 HDL 血浆水平显著且持续增加,在 16 周内达到相似的程度。从载脂蛋白负载的巨噬细胞中去除胆固醇的生成 HDL 的活性在两组中相似。我们的数据表明,AAV8 介导的肌内基因转移人 ApoA-I 可导致 ApoA-I 和功能性 HDL 的显著和持续增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验